Last reviewed · How we verify
SY-009 capsules
At a glance
| Generic name | SY-009 capsules |
|---|---|
| Sponsor | Suzhou Yabao Pharmaceutical R&D Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus (PHASE2)
- Single Ascending Oral Doses of SY-009 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SY-009 capsules CI brief — competitive landscape report
- SY-009 capsules updates RSS · CI watch RSS
- Suzhou Yabao Pharmaceutical R&D Co., Ltd. portfolio CI